Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study
- 31 January 2002
- journal article
- clinical trial
- Published by Elsevier BV in European Urology
- Vol. 41 (1), 54-61
- https://doi.org/10.1016/s0302-2838(01)00016-1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- Preclinical Pharmacology of α1-Adrenoceptor AntagonistsEuropean Urology, 1999
- A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionEuropean Urology, 1999
- Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General PracticeProstate Cancer and Prostatic Diseases, 1998
- Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.European Urology, 1998
- Clinical uroselectivity: evidence from patients treated with slow‐release alfuzosin for symptomatic benign prostatic obstructionBritish Journal of Urology, 1997
- Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic HyperplasiaEuropean Urology, 1997
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with AlfuzosinPublished by Wiley ,1992
- Alfuzosin for treatment of benign prostatic hypertrophyThe Lancet, 1991